Showing results (21-30 of 43) with videos related to
Sort By:
Pageof 5
Cancer Research|November 1, 1992
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patientsJ A Foekens, M Schmitt, W L van Putten, et al.British Journal of Cancer|December 1, 1994
Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancerJ A Foekens, H Portengen, M P Look, et al.British Journal of Cancer|November 1, 1989
Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cellsM Bontenbal, A M Sieuwerts, J G Klijn, et al.European Journal of Cancer (Oxford, England : 1990)|January 3, 2003
Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancerC H Smorenburg, A J ten Tije, J Verweij, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancerJ M Nabholtz, K Gelmon, M Bontenbal, et al.Neurology|March 4, 1998
Lhermitte's sign following chemotherapy with docetaxelM J van den Bent, P H Hilkens, P A Sillevis Smitt, et al.European Journal of Cancer (Oxford, England : 1990)|August 10, 2000
Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklistJ A Kramer, D Curran, M Piccart, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Paclitaxel (Taxol) induces cumulative mild neurotoxicityJ M van Gerven, J W Moll, M J van den Bent, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 1997
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast CancerM J Piccart, J Klijn, R Paridaens, et al.Breast Cancer Research and Treatment|January 1, 1992
Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancerM Bontenbal, A S Planting, C J Rodenburg, et al.Pageof 5